Company intelligence / Profile preview
ResoTher Pharma
Holte, Denmarkresotherpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ResoTher Pharma has initiated dosing in its Phase 2a clinical trial evaluating RTP026, an Annexin A1-derived peptide therapeutic, in patients with myocardial infarction. Preclinical data show that RTP026 regulates immune cell recruitment and promotes tissue repair by mimicking endogenous resolution of inflammation. The company’s approach addresses unmet needs in cardiovascular care by targeting the inflammatory component not addressed by current therapies.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- PeptidesRecombinant peptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharma partnerships publicly disclosed; received grant funding from European Innovation Council and Nordic Mentor Network of Entrepreneurship.
Beyond the preview
Go deeper on ResoTher Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ResoTher Pharma.